Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COMFORT-PFO
NCT07629635Phase 3Recruiting
- Sponsor
- Columbia University
- Start
- Oct 2026
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in migraine (2 arms), sponsored by Columbia University. Primary endpoint: Reduction in Monthly Migraine Days. Started Oct 2026; status: recruiting.
02
Conditions
migraine
Beyond the preview
Go deeper on NCT07629635.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07629635.